Cite
HARVARD Citation
Markovà, J. et al. (2019). Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. International journal of neuroscience. pp. 119-128. [Online].